On the Record · Shire
Shire competitors, on the record
The companies Shire names as competitors in its annual reports, 2015 to 2017, and the companies that name Shire, each with the sentence and the filing.
Who Shire names
| Company | Named in |
|---|---|
| Allergan | 2017 |
| Amicus | 2017 |
| Bayer | 2017 |
| Bioverativ | 2017 |
| CSL | 2017 |
| Genzyme | 2017 |
| Medac | 2017 |
| Novo Nordisk | 2017 |
| Octapharma | 2017 |
| Pfizer | 2017 |
| SOBI | 2017 |
In its own words
Allergan
Word for word“XIIDRA competes against Allergan's RESTASIS (a prescription topical immunomodulator indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca) and various over the counter artificial tear products.” 10-K for 2017
Amicus, Genzyme
Word for word“REPLAGAL primarily competes with Genzyme’s FABRAZYME and Amicus' GALAFOLD in markets outside the U.S.” 10-K for 2017
Bayer, Bioverativ, CSL, Novo Nordisk, Octapharma, Pfizer, SOBI
Word for word“The principal sources of competition for ADVATE and ADYNOVATE globally are: XYNTHA/REFACTO AF (Pfizer and SOBI); KOGENATE (Bayer); HELIXATE (CSL); KOVALTRY (Bayer); Iblias (CSL); ELOCTATE/ELOCTA (Bioverativ and SOBI); NOVOEIGHT (Novo Nordisk); and NUWIQ (Octapharma); Afstyla (CSL).” 10-K for 2017
Medac
Word for word“ONCASPAR competes with Medac’s SPECTRILA, a recombinant version of asparaginase which was recently approved in the EU.” 10-K for 2017
Who names Shire
Companies whose own annual reports name Shire as a competitor.
Word for word“F-79 Restasis ® Competitor Litigation . Shire, which offers the dry-eye disease drug Xiidra ® , sued subsidiaries of the Company in U.S.” 10-K for 2019
Word for word“A number of companies, including some mid-to-large biopharmaceutical companies, such as Alnylam Pharmaceuticals, Bayer AG, Novo Nordisk, CSL Ltd., Pfizer Inc., Roche Holding AG, Sanofi Genzyme and Shire Plc., currently market or are pursuing the development of products for the treatment of hemophilia.” 10-K for 2017
Read from Shire’s annual reports (10-K for 2017, 10-K for 2016, 10-K for 2015) and the financial data it files with the SEC, as of 2018-02-20. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.